Trials / Terminated
TerminatedNCT04439071
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19)
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 189 (actual)
- Sponsor
- PTC Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PTC299 | Oral tablets |
| OTHER | SOC | As defined per local written policies or guidelines. |
| DRUG | Placebo | Oral tablets |
Timeline
- Start date
- 2020-07-09
- Primary completion
- 2022-07-20
- Completion
- 2022-07-20
- First posted
- 2020-06-19
- Last updated
- 2023-06-26
- Results posted
- 2023-06-26
Locations
41 sites across 11 countries: United States, Australia, Belgium, Brazil, Colombia, France, Mexico, Poland, Portugal, South Africa, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04439071. Inclusion in this directory is not an endorsement.